{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:14:13Z","timestamp":1772306053363,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0148924","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T18:55:49Z","timestamp":1455303349000},"page":"e0148924","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens"],"prefix":"10.1371","volume":"11","author":[{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A.","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"L\u00f3pez-Ruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Rios-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Jim\u00e9nez-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Marquez-Solero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Terr\u00f3n-Pern\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Tellez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Orihuela-Ca\u00f1adas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaira","family":"Palacios-Baena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vinuesa-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Fajardo-Pico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Romero-Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Ojeda-Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pasquau-Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"18","key":"ref1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy","volume":"339","author":"DV Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM199810293391802","article-title":"A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients","volume":"339","author":"G Pialoux","year":"1998","journal-title":"N Engl J Med"},{"issue":"9123","key":"ref3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(98)06193-5","article-title":"Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study","volume":"352","author":"MH Reijers","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)","volume":"40","author":"JR Arribas","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jac\/dkn103","article-title":"Long-term (4 years) efficacy of lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"61","author":"F Pulido","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"JR Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","article-title":"Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial","volume":"65","author":"JL Meynard","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long-term efficacy of darunavir\/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study","volume":"67","author":"MA Valantin","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkr199","article-title":"96 week results from the MONET trial: a randomized comparison of darunavir\/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies\/mL at baseline","volume":"66","author":"N Clumeck","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e22003","DOI":"10.1371\/journal.pone.0022003","article-title":"Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis","volume":"6","author":"S Mathis","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-10-3","article-title":"Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting","volume":"10","author":"JR Arribas","year":"2013","journal-title":"AIDS Res Ther"},{"key":"ref12","year":"2015"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"HF G\u00fcnthard","year":"2014","journal-title":"JAMA"},{"key":"ref14","unstructured":"European AIDS Clinical Society. European Guidelines for treatment of HIV infected adults in Europe. October 2015. Version 8. Available: http:\/\/eacsociety.org\/Guidelines.aspx<\/ext-link>. Accessed 1 December 2015."},{"key":"ref15","unstructured":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (January 2015). Available: http:\/\/www.gesida-seimc.org\/index.php<\/ext-link>. Accessed 1 March 2015."},{"issue":"Suppl 1","key":"ref16","first-page":"1","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update)","volume":"15","author":"I Williams","year":"2014","journal-title":"HIV Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"19034","DOI":"10.7448\/IAS.17.1.19034","article-title":"French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults","volume":"17","author":"B Hoen","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/11598380-000000000-00000","article-title":"Budget impact analysis of switching to darunavir\/ritonavir monotherapy for HIV-infected people in Spain","volume":"10","author":"J Pasquau","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1310\/hct1103-133","article-title":"Comparative cost-efficacy analysis of darunavir\/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States","volume":"11","author":"AJ Brogan","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"4","key":"ref20","first-page":"222","article-title":"Recommendations from the GESIDA\/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)","volume":"27","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref21","unstructured":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV\u2010infected adults. Version 5. 2009. Available: http:\/\/www.eacsociety.org\/files\/2009_eacsguidelines-v5-english.pdf<\/ext-link>. Accessed 1 March 2014."},{"issue":"5","key":"ref22","first-page":"156","article-title":"Update of the drug resistance mutations in HIV-1: December 2010","volume":"18","author":"VA Johnson","year":"2010","journal-title":"Top HIV Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2334-12-100","article-title":"HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability","volume":"12","author":"J Ruelle","year":"2012","journal-title":"BMC Infect Dis"},{"key":"ref24","year":"1996"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e41390","DOI":"10.1371\/journal.pone.0041390","article-title":"Similar evolution of cellular HIV-1 DNA level in darunavir\/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks","volume":"7","author":"S Lambert-Niclot","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/QAD.0000000000000060","article-title":"Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir\/ritonavir monotherapy","volume":"28","author":"A Torres-Cornejo","year":"2014","journal-title":"AIDS"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/1469-0691.12521","article-title":"Immune activation throughout a boosted darunavir monotherapy simplification strategy","volume":"20","author":"OJ Benmarzouk-Hidalgo","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/QAD.0000000000000312","article-title":"Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes","volume":"28","author":"D Vinuesa","year":"2014","journal-title":"AIDS"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1128\/AAC.00725-10","article-title":"Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600\/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy","volume":"54","author":"S Lambert-Niclot","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","unstructured":"Yeh RF, Hammill HA, Fiscus SA, et al: Single Agent Therapy (SAT) with lopinavir\/ritonavir (LPV\/r) controls HIV-1 viral replication in the female genital tract. [Abstract P7.7\/02]. In: Program and abstracts of the 11th European AIDS Clinical Society Conference. Madrid. Spain. 2007."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Yeh RF, Letendre S, Novak I, et al. Single-agent therapy with lopinavir\/ritonavir controls HIV-1 viral replication in the central nervous system. [Abstract E-177]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California. 2007.","DOI":"10.2217\/17469600.1.1.13"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"e69493","DOI":"10.1371\/journal.pone.0069493","article-title":"Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy","volume":"8","author":"I P\u00e9rez-Valero","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/QAI.0000000000000337","article-title":"A Comparative Study of Neurocognitively Impaired Patients Receiving Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy","volume":"67","author":"M Est\u00e9banez","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350901400210","article-title":"Risk factors for loss of virological suppression in patients receiving lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"14","author":"F Pulido","year":"2009","journal-title":"Antivir Ther"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"S Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0148924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T01:47:20Z","timestamp":1654307240000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0148924"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0148924","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}